chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Current-Hair loss; Skin rash; intermittent left lower sharp back pain; swollen lymph node; headaches; arthritis pain worse; arthritis pain worse; tired; hair shedding; flue like Symptoms; Other vaccine same date vaccine date 09Sep2021; dose number=3; dose number=3; This is a spontaneous report from a contactable consumer or other non hcp. A 62-years-old female patient received bnt162b2 (PFIZER-BIONTEC COVID-19 VACCINE, Formulation: solution for injection, Batch/Lot Number: EW0185 MUSC), via an unspecified route of administration, administered in Arm Left on 09Sep2021 (age at vaccination 62-Years-old) as dose 3 (booster), single for COVID-19 immunization; SHINGRIX, via an unspecified route of administration from 09Sep2021 (Batch/Lot number was not reported) to 09Sep2021, at unspecified dose for an unspecified indication . Medical history included arthritis from an unknown date and unknown if ongoing , hypersensitivity from an unknown date and unknown if ongoing , blood cholesterol increased from an unknown date and unknown if ongoing , blood iron decreased from an unknown date and unknown if ongoing , seasonal allergy from an unknown date and unknown if ongoing , food allergy from an unknown date and unknown if ongoing. Concomitant medication(s) included amfetamine aspartate, amfetamine sulfate, dexamfetamine saccharate, dexamfetamine sulfate (ADDERALL); chorionic gonadotrophin (HTROP); colecalciferol (VIT D [COLECALCIFEROL]); calcium (CALCIUM) and fish/flack seed all taken for an unspecified indication, start and stop date were not reported. The patient previously took, niacin and experienced drug hypersensitivity, statins and experienced drug hypersensitivity. Patient previously received bnt162b2 (PFIZER-BIONTEC COVID-19 VACCINE, Formulation: solution for injection, Batch/Lot Number: EL1284), via an unspecified route of administration, administered in Arm Left on 06Jan2021 (age at vaccination 61-Years-old) as dose 1, single for COVID-19 immunization and bnt162b2 (PFIZER-BIONTEC COVID-19 VACCINE, Formulation: solution for injection, Batch/Lot Number: EL3249 MUSC), via an unspecified route of administration, administered in Arm Right on 26Jan2021 (age at vaccination 61-Years-old) as dose 2, single for COVID-19 immunization. on an unspecified date patient experienced current-Hair loss, Skin rash, intermittent left lower sharp back pain after vac- swollen lymph node, headaches, arthritis pain worse, tired, hair shedding, flue like Symptoms. HAIR LOSS is my biggest concern and 09Sep2021, other vaccine same date vaccine date 09sep2021, dose number=3. Patient did not received any treatment. The outcome events other vaccine same date vaccine date 09sep2021, dose number=3 was unknown and rest all was not received.  Follow-up attempts are completed. No further information is expected.
The pt presented with intractable seizures of unknown etiology. She has been treated by neurologists and other therapists at different hospitals.
Headache (still on day 4) & horrible itchy, hives (despite being on 2 antihistamines daily).  Hives are on my face, neck, chest, & both arms.  The incessant itching is keeping me awake at night.  Nothing is helping.
Lump in arm at vaccine site. Pain at injecting site and pain radiating into underarm area.
little soreness in the arm for a day; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (little soreness in the arm for a day) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Sarcoma and Carcinoma.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYALGIA (little soreness in the arm for a day). At the time of the report, MYALGIA (little soreness in the arm for a day) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was Reported.  No treatment medication was Reported.
Unusual sleeping pattern, projectile vomiting several times within an hour, dry heaves, slight temp. Not verbaly interactive, vomit every time after a feeding and diarrhea also. Lasted about 36 hours (some symptoms)
LETHARGY; BODY ACHE; HEADACHE; This spontaneous report received from a patient concerned a 36 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine (suspension for injection, route of admin not reported, batch number: 1808609, expiry: UNKNOWN) dose was not reported to right deltoid administered on 31-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 01-APR-2021, the subject experienced lethargy. On 01-APR-2021, the subject experienced body ache. On 01-APR-2021, the subject experienced headache. The action taken with covid-19 vaccine was not applicable. The patient had not recovered from lethargy, body ache, and headache. This report was non-serious.
Dizziness, Arthralgia, Fever, Diarrhea, NauseaVomiting, chills, injection site pain and swelling Narrative:
It cause my relapse to worsen and I have had diarrhea since. Still dealing with it. I have lost weight and feel horrible.
Red hives on top of head, forehead, back of head and neck, unusual crying for hours can't be consoled, loss of appetite.
Developed pericarditis/pericardial effusion 1 wk after. Does have a previous h/o pericardial effusion.
I experienced a sudden onset menstrual period after not having one for over two years.  I began spotting the evening I received the shot and bleeding the next day.
On 8/24/2020, the patient was administered improperly stored PROQUAD (reconstituted with properly stored Merck STERILE DILUENT).; This spontaneous report has been received from a medical assistant concerning a 4-year-old female patient of unknown ethnicity. The patient's medical history, known allergies/reactions, medical history and concomitant medications were not reported.   On 24-AUG-2020, the patient was vaccinated with an improperly stored Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (Lot # T005406 with expiration date 12-AUG-2021; rHa albumin status; dosage regimen not reported), subcutaneously as prophylaxis (indication also reported as ''well check''). The vaccine was reconstituted with a properly stored sterile diluent. The administered Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) had been exposed to multiple temperature excursions between -9 degree celsius (C) to 8C (average- 6.1C) during an unknown time frame (no previous excursions). The call was performed due to a data logger.
Skin become worse; Scalp and feet being worse; This spontaneous case was reported by a consumer and describes the occurrence of SKIN DISORDER (Skin become worse) and CONDITION AGGRAVATED (Scalp and feet being worse) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) for Plaque psoriasis.    No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and RISANKIZUMAB (SKYRIZI [RISANKIZUMAB]) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced SKIN DISORDER (Skin become worse) and CONDITION AGGRAVATED (Scalp and feet being worse). At the time of the report, SKIN DISORDER (Skin become worse) had resolved and CONDITION AGGRAVATED (Scalp and feet being worse) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. No concomitant medications were reported. No treatment medications were reported. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Employee states after administration of Tdap at 8AM 7/26/10, that evening had fever, headache, myalgia, pain under left axilla at 9PM. 7/28/10 symptoms mostly resolved - some pain (L) axilla - T-98.6.
Information has been received from a Registered Nurse (R.N.) concerning a patient with who was vaccinated with "at least one, if not two doses of MMR II in the past" and then had negative titers for rubella. The nurse stated the vaccine doses were not given in their office. No other adverse reactions were reported. At the time of report the outcome was unknown. Follow up information was received from a Registered Nurse (R.N.) reported that there was no adverse experience. No further information is available.
Pt. recieved the HPV in the right deltoid and the MCV4 in the left deltoid. Pt was seated as the vaccinations were given. After about 3 minutes, Pt wanted to stand in the hallway to wait for his father. Pt stated that he felt "good." After about 5 minutes of standing in the hallway, patient fainted and fell to the floor. Patient reported that his head got cloudy and he knew he was going to faint. Patient's father reported that patient has fainted in the past after shots.
Patient presented for well care and received Hepatitis A vaccine.  That evening he developed fever to 104.  The fever persisited.  Around 0200 on 8/31/04 the patient went to the ED and was told he had tonsillitis and was given an Rx for Penicillin.  No throat culture was done.  Follow up exam on 9/1/04 showed papulovesicular lesions on the anterior pillars consistent with herpangina.
Student received second dose of AVA 4/16/04 in the immunization clinic. On 04/19/04, reported back to nurse with the following symptoms: Right arm red, swollen and warm to touch. Clinic nurse sent her to the affiliated urgent care center where she was treated. She returned to the clinic 04/20/04 and the affected arm was much improved.
he reported having increased soreness and stiffness to his knees, hips, knuckles, elbows,and shoulders; he reported having increased soreness and stiffness to his knees, hips, knuckles, elbows,and shoulders; swelling in his joints; This is a spontaneous report received from contactable reporter(s) (Other HCP) for a Pfizer sponsored program. The reporter is the patient.  A 62 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE, Manufacturer: Unknown), for Covid-19 immunization; Covid-19 vaccine (DOSE 2, SINGLE, Manufacturer: Unknown), for Covid-19 immunization. The following information was reported: ARTHRALGIA (non-serious), JOINT STIFFNESS (non-serious), outcome "unknown" and all described as "he reported having increased soreness and stiffness to his knees, hips, knuckles, elbows,and shoulders"; JOINT SWELLING (non-serious), outcome "unknown", described as "swelling in his joints".  Additional Information: Patient reported in Nov being off of xeljanz for 2 weeks because he got the covid-19 booster. While off xeljanz, he reported having increased soreness and stiffness to his knees, hips, knuckles, elbows, and shoulders. He also reported once in a while having stiffness and swelling in his joints. Md is aware. Patient also reported sometimes would be late getting his medication due to previous pharmacy being late on shipping his medication. Unknown how many days he was late as well as any adverse effect. Md was aware of the delays from previous pharmacy. Dose 11mg, Once daily via oral route for Rheumatoid Arthritis. Output Form Id: 750916 and Program ID: 141003 was reported.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
devel severe, gen, erythematous papular rash w/vesiculation & purpura on lower extremities;crusting appeared over shins;new areas of rash recurred for up to 6wk post vax;
Occipital neuritis - Pain in back of head, stiff neck. Time line was about 1 wk after being vaccinated. Treatment: Steroids, pain med, trigger point injection.
Fever, chills, headache, chest pain, nausea, dizzy, diarrhea, in bed 33 hrs slept off and on. 10/2 Still having chest pain and dizziness scheduled for angiogram 10-17-16.
Ear pain, pulling on ear, not sleeping well at night, not taking bottles well, irritability: since day vaccines given.
MD reported that pt recvd diluent only for HIB vax & another pt was vaxed w/properly mixed HIB on the same day; MD was not sure which pt recvd the diluent & which pt recvd the vax; 2 wks later 1 of these 2 children devel a rash;
METALLIC TASTE; This spontaneous report received from a consumer concerned a 67 year old male. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 205A21A, and batch number: 205A21A expiry: UNKNOWN) dose was not reported, administered on 14-MAY-2021 for prophylactic vaccination. No concomitant medications were reported. On 14-MAY-2021, the subject experienced metallic taste. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from metallic taste. This report was non-serious.
Severe vomiting began at 10 pm, 5/22/2021, and lasted until 3:30 am, 5/23/2021 (with 30-45 minute intervals between incidents). Patient slept until 8 am, 5/23/2021, and began re-hydrating their system at 9 am. No other adverse effects so far.
Customer came in with red area on arm where vaccine had been given.  She said it was swollen and was warm to the touch.
Sore throat started two days after and has lasted 2 weeks. Does not seem to get better.  Diarrhea and slight body aches as well.
feeling itchy on her back and legs, experiencing a lot of itching, her skin is itching; This is a spontaneous report from a contactable consumer (patient). A 62-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration, administered in Arm Right on 24Feb2021 (Batch/Lot Number: EN6200) (at the age of 62 years) as DOSE 1, SINGLE for covid-19 immunisation. Medical history was none. There were no concomitant medications. The patient experienced feeling itchy on her back and legs, experiencing a lot of itching, her skin is itching on 26Feb2021 with outcome of not recovered.    No follow-up attempts are possible. No further information expected.
Information has been received from a consumer, who is a registered nurse, concerning her son, 4 years old at the time of the report, who in July 1999, was vaccinated with a dose of MMR II (lot not given). After the vaccination, in July 1999, the pt developed a fever that resolved within a day. "Sometime later the child stopped talking and became detached." At the age of 22 months the child was diagnosed, by a doctor of philosophy, with "PPD with moderate autism." Unspecified medical attention was sought. Upon internal review, autism was determined to be an other important medical event. Additional info has been requested. Follow up info received from the pt's mother indicated that the pt "had early speech developed prior to 12 mo then later slowly slipped into his own world with complete loss of speech. He had early intervention and is developing normally now with few speech problems. Hearing test were normal. This symptom occurred slowly over time after the MMR vaccine was given to him." Follow up info received from a physician indicated that the pt had no allergies, no past medical history and there was no illness at the time of vaccination. The physicians also indicated that there were no adverse events. Upon internal review, autism was determined to be an other important medical event (OMIC). Additional info is not expected.
no adverse event; multiple patients were vaccinated with an improperly stored vaccine; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not reported.  On 16-MAY-2019, the patient was vaccinated with an improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ), 2 ml, orally (lot # R034700, expiry date 16-JUN-2020) for prophylaxis. The vaccine was exposed to a temperature of 34.2 Fahrenheit degrees for 4 hours and 54 minutes. Digital data logger was involved. There were no previous temperature excursions. No adverse effects were reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1906USA011674: US-009507513-1907USA000862: US-009507513-1907USA000882: US-009507513-1907USA000883: US-009507513-1907USA000884: US-009507513-1907USA000885: US-009507513-1907USA000886: US-009507513-1907USA000887: US-009507513-1907USA000888: US-009507513-1907USA000889: US-009507513-1907USA000890: US-009507513-1907USA000891: US-009507513-1907USA000892: US-009507513-1907USA000893: US-009507513-1907USA000894: US-009507513-1907USA000895: US-009507513-1907USA000896: US-009507513-1907USA000897: US-009507513-1907USA000898: US-009507513-1907USA000899: US-009507513-1907USA000900: US-009507513-1907USA000902: US-009507513-1907USA000903: US-009507513-1907USA000904: US-009507513-1907USA000905: US-009507513-1907USA000906: US-009507513-1907USA000907: US-009507513-1907USA000908: US-009507513-1907USA000909: US-009507513-1907USA000910: US-009507513-1907USA000911: US-009507513-1907USA000912: US-009507513-1907USA000913: US-009507513-1907USA000914: US-009507513-1907USA000915: US-009507513-1907USA000916: US-009507513-1907USA000917: US-009507513-1907USA000918: US-009507513-1907USA000919: US-009507513-1907USA000920: US-009507513-1907USA000921: US-009507513-1907USA000922: US-009507513-1907USA000923: US-009507513-1907USA000924: US-009507513-1907USA000925: US-009507513-1907USA000926: US-009507513-1907USA000927: US-009507513-1907USA000928: US-009507513-1907USA000929: US-009507513-1907USA000930: US-009507513-1907USA000931: US-009507513-1907USA000932: US-009507513-1907USA000933: US-009507513-1907USA000934: US-009507513-1907USA000935: US-009507513-1907USA000936: US-009507513-1907USA000937: US-009507513-1907USA000938:
3 days after, Pt. arm was red and tender - 2 in. in diameter and warm to touch. Pt. went to clinic, and received BACTRIM DS for 10 days to cover a possible skin infection. Pt. Allergic to PCN.
13 hours after shot, right arm warm and tender, nausea. 22 hours after shot had seizure like activity with staring into space, not responding, right arm twitching.  Lasted 2 minutes.  Eventually responded to name.  A 2nd episode occurred a couple hours later.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID: (Unknown). The reporter is the patient. A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MYOCARDIAL INFARCTION (medically significant), outcome "unknown", described as "heart attack". Clinical information: The reporter (patient) stated, I had a heart attack about two weeks after my first shot. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Headache; Swelling in shot areas; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a patient and describes the occurrence of HEADACHE (Headache) and VACCINATION SITE SWELLING (Swelling in shot areas) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced HEADACHE (Headache) and VACCINATION SITE SWELLING (Swelling in shot areas). At the time of the report, HEADACHE (Headache) and VACCINATION SITE SWELLING (Swelling in shot areas) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Reporter did not allow further contact
Nine days after, extreme chills, headache, hip and back pain. Progressively worsened to where I was unable to walk. One week later I was unable to move my arms above the elbow. After 3 appts with my Primary Care, a rheumatologist and a vascular surgeon, I was diagnosed with Polymyalgia Rheumatica and Temporal Arteriyis. Being treated with high dose steroids (60 MG daily) and Actemra injections.
Information has been received from a physician concerning a female with no drug reactions or allergies who was vaccinated with a dose of Varivax. Subsequently, 24 hours after vaccination, the patient experienced a localized rash on her legs described as vesicles. Subsequently, the patient recovered 2 days later. Unspecified medical attention was sought. Additional information has been requested.
No adverse event; Received Moderna Covid 19 vaccine after the expiration date; This spontaneous case was reported by a patient and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Moderna Covid 19 vaccine after the expiration date) and NO ADVERSE EVENT (No adverse event) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 006021A and 0A242A1) for COVID-19 vaccination.     Patient did not tested positive for COVID-19.  Concurrent medical conditions included Food allergy (Dairy), Dust allergy and Allergy to animals.   On 24-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Sep-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-Sep-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Moderna Covid 19 vaccine after the expiration date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Received Moderna Covid 19 vaccine after the expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.            Concomitant medication was not provided.  Treatment information was not provided.
Patient was functioning normally before receiving vaccine per nursing home staff and patient's wife. Able to walk and eat/drink, speak, and communicate at his usual baseline. Two days after receiving his vaccine he developed an inability to speak and change in behavior. Patient was evaluated in the ER for altered mental status and was noted to be agitated. Head CT done, provider recommended head/neck/carotid CTA but not done at this facility. Patient was admitted to Hospital and treated for metabolic encephalopathy. PEG tube replaced (had previously after stroke in October 2021) and patient was given an insulin drip per wife. Writer did not obtain records from admitting facility. Patient was hospitalized from 2/20/22 to 3/8/22. Patient remains worsened from baseline per wife and nursing home staff. This situation came to my attention when he was seen in the ER today (3/9/22) for high blood sugar levels in the 900s and has now been admitted to the hospital.